Viatris Prevails Over Novo Nordisk in Semaglutide Patent Dispute, Paving Way for Potential Wegovy Generic
U.S. patent ruling favors Viatris, removing a significant barrier to launching a generic version of Novo Nordisk’s blockbuster weight-loss drug Wegovy
In a key patent litigation outcome, Viatris has successfully challenged Novo Nordisk’s semaglutide patent, which covers the active ingredient in the weight management drug Wegovy. The decision clears a major hurdle for Viatris to pursue generic versions of the medication, potentially impacting the competitive landscap…